Featured Courses

Update on Antiplatelet and Antithrombotic Therapy in the Cardiometabolic Patient | myCME

AMA PRA Category 1 Credit(s)^TM, CNE Contact Hour(s), CE for Pharmacists, CPEU Credit

This Clinical Brief is a short, to-the-point, online enduring activity covering key points, clinical pearls, and expert perspectives discussed throughout the CMHC West 2020 Live Online session.

Critical Impact of Inflammation in Lysosomal Diseases: Unlocking Future Treatments and Improving Outcomes | myCME

AMA PRA Category 1 Credit(s)^TM, CNE Contact Hour(s)

The goal of this activity, which was held at WORLDSymposium 2021 will be to address the critical role of inflammation in lysosomal diseases, with a specific focus on inflammation in Gaucher disease, mucopolysaccharidosis type II (MPS II), and metachromatic leukodystrophy (MLD). Gaucher disease, MPS II, and MLD are three lysosomal diseases in which inflammation plays a significant role in disease progression and associated neurodegeneration.

Glycemic Control and Beyond: Harnessing the Potential of SGLT-2 Inhibition Across Disease States | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), CE for Pharmacists

SGLT-2 inhibitors help patients with T2DM achieve glycemic control and promote weight loss, reductions in blood pressure, and significant benefits in heart failure and renal outcomes.

The Now Generation and New Generation of GLP-1 RAs: Reshaping the Care of Patients with Type 2 Diabetes

AMA PRA Category 1 Credit(s)^TM

GLP-1 RAs are associated not only with substantial A1C reductions and enhanced glycemic control, but greater weight loss compared to many other agents among patients with T2DM.

AACE Advanced Technology for Diabetes Care | myCME

AMA PRA Category 1 Credit(s)^TM, ABIM MOC Credit, ANCC Contact Hour(s), CE for Pharmacists, AAPA Category I CME credit

Two video-based, pre-recorded webinars with presenters who are experts in the field will cover the following topics: Exploring CGM, Identifying Patients Who Will Benefit from CGM , and Emerging Technologies: A Better Life for Patients with Diabetes

Preventing Cardiovascular Events in High-Risk Diabetes Patients with CAD | myCME

AMA PRA Category 1 Credit(s)^TM, CNE Contact Hour(s), CE for Pharmacists, CPEU Credit

Diabetes increases the risk of cardiovascular and thrombotic adverse events in patients with CAD compared to patients with these conditions and no concomitant diabetes. This virtual symposium will review several recently-completed and ongoing clinical trials evaluating the efficacy and safety of current antiplatelet therapy to prevent adverse events in these high-risk patients, including the use of more aggressive and specific antithrombotic agents in this setting.

HIV with Comorbid Conditions | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), AAPA Category I CME credit, CE for Pharmacists

Experts in the management of patients living with HIV discuss issues currently of particular significance including the effect of aging and associated HIV-related comorbidities, the increasingly important role of primary care providers, and the effect of COVID-19. Emphasis will be placed on the metabolic syndrome and its effect on HIV management.

Beyond Diabetes: The Cardiometabolic Profile – Virtual Simulation | myCME

AMA PRA Category 1 Credit(s)^TM, NCPD Contact Hour(s)

In this AI-based virtual patient simulation (VPS) series, you will meet two unique patients with diabetes and cardiovascular risk who will test your ability to assess their condition and personalize their treatment. The simulation platform allows for real-world clinical decision-making in a risk-free learning environment.

Hereditary Pheochromocytoma and Paraganglioma

AMA PRA Category 1 Credit(s)^TM

The goal of this activity is to provide clinicians with a brief review of hereditary paraganglioma-pheochromocytoma syndrome, SDHD-Associated tumor risks, and surveillance recommendations.

Blocking TSH-Receptor Antibodies in Autoimmune Thyroid Disease | myCME

AMA PRA Category 1 Credit(s)^TM, CE for Nurse Practitioner

The effect of TSH-receptor stimulating and TSH-receptor blocking immunoglobulins in the management of autoimmune thyroid disease. The updated ATA / AACE guidelines will be discussed.

Pediatric GHD: Working Together To Ensure Success

AMA PRA Category 1 Credit(s)^TM

The Endocrine Society and The France Foundation is providing this enduring material for any pediatric and general endocrinologist, family physician, pediatrician, nurse practitioner, or physician assistant who is interested in learning more about pediatric GHD and its management.

100 Years of Innovation in Insulin Therapy

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s)

This program is designed to review key advances in insulin therapy from its introduction in the early 1920s to current innovations.